In fibrotic livers, collagen producing hepatic stellate cells (HSC) represent a major target for antifibrotic therapies. We designed liposomes with surface-coupled mannose 6-phosphate (M6P) modified human serum albumin (HSA) to target HSC via the M6P receptor. In this study we determined the pharmacokinetics and target specificity of M6P-HSA-liposomes in a rat model of liver fibrosis. Ten minutes after injection of [ 3 H]-M6P-HSA-liposomes 90% of the dose has cleared the circulation. The blood elimination of these liposomes was counteracted by free M6P-HSA and polyinosinic acid, a competitive inhibitor of scavenger receptors. The M6P-HSA-liposomes accumulated in HSC. However, also Kupffer cells and endothelial cells contributed to the uptake of M6P-HSA-liposomes in the fibrotic livers. Polyinosinic acid inhibited the accumulation of the liposomes in Kupffer cells and liver endothelial cells, but not in HSC. PCR analysis revealed that cultured HSC express scavenger receptors. This was confirmed by Western blotting, although activation of HSC diminishes scavenger receptor protein expression. In conclusion, in a rat model for liver fibrosis M6P-HSA-liposomes can be efficiently targeted to non-parenchymal cells, including HSC. M6P receptors and scavenger receptors are involved in the cellular recognition of these liposomes, allowing multiple pharmacological interference in different pathways involved in the fibrosis.
Introduction
The potential of liposomes as a drug carrier system has been extensively investigated. Various types of targeted liposomes have been developed aiming at specific populations of liver cells. Hepatocytes can be targeted using galactosylated liposomes [1] [2] [3] or asialofetuin grafted vesicles [4] . Liposomes that are modified with aconitylated human serum albumin predominately accumulate in liver endothelial cells (LEC) [5] and mannosylated liposomes are recognised by Kupffer cells (KC) [6, 7] . So far, no studies have been reported on targeting of liposomes to hepatic stellate cells (HSC), which, in addition to KC and LEC, comprise an important population of non-parenchymal cells in the liver.
In healthy organs, HSC are mainly responsible for storage of vitamin A [8] . In diseased livers, HSC play a central role in the processes that lead from chronic liver injury to fibrosis. A variety of factors including, chronic hepatitis B or C infections, alcoholism and metabolic disorders, have been identified as possible causes of liver fibrosis. In the initial stages of the disease, damage to hepatocytes, biliary epithelial cells and other hepatic cells induces the production of different factors by these [9] . Upon stimulation by these cytokines, HSC become activated and transdifferentiate into myofibroblast-like cells. Activated HSC are characterised by loss of vitamin A and a high rate of proliferation [10] . Moreover, they migrate towards the site of injury and produce excessive amounts of interstitial collagen, mainly type I and III, which disposition leads to impairment of liver structure and functions. HSC acquire also contractile properties that allow them to control sinusoidal blood flow [11] and contributing to the portal hypertension occurring in cirrhotic patients. Liver fibrosis is a long-term disease which is the most common non-neoplastic cause of death among hepatobiliary and digestive diseases [12] . In addition, epidemiological prognoses indicate that, in the coming years the prevalence of liver fibrosis will significantly increase due to increasingly occurring cases of hepatitis C infections [13] and the rising number of patients with non-alcoholic steatohepatitis [14] . So far no effective treatment has been established other than removal of primary cause of the disease and liver transplantation for severe fibrosis. Currently, a large variety of drugs is being investigated for antifibrotic effects [12] which can be classified according to their therapeutic effects, including reduction of inflammation, antioxidant properties or promotion of extracellular matrix degradation. Many of the compounds aim at HSC to inhibit their activation and proliferation, reduce ECM production by HSC, neutralize HSC contractile responses or stimulate HSC apoptosis. Although, these compounds show promising effects in vitro, the in vivo tests give disappointing results, mainly due to the lack of cell specificity. Therefore, drug carrier system targeted to the cells that are pivotal in the development of fibrosis represent an attractive prospect for future therapies. In a rat model of liver fibrosis mannose 6-phosphate modified human serum albumin (M6P-HSA) was shown to accumulate in HSC [15] and the uptake of this protein by HSC was demonstrated to be mediated by mannose 6-phosphate/insulin like growth factor II (M6P/IGF II) receptor [16] . In fibrotic livers, HSC express an increased amount of the M6P/ IGF II receptor [17] that is involved in the activation of transforming growth factor β (TGF-β) [18, 19] , a key profibrotic cytokine. Liposomes used as drug carriers in the anticancer treatment have proven their potential in the therapy of chronic disease. We designed a liposomal drug carrier to HSC by coupling mannose 6-phosphate-modified human serum albumin (M6P-HSA) to the surface of liposomes. Previously, we demonstrated a high degree of association of M6P-HSA liposomes with cultured HSC and we showed that these liposomes can be targeted to HSC in fibrotic livers [20] .
In the current in vivo studies, using bile duct ligated (BDL) rats as a model of liver fibrosis, we determined the pharmacokinetic properties and the biodistribution of M6P-HSA liposomes in diseased animals. Subsequently, we analyzed whether next to HSC, KC and LEC play a role in the accumulation of M6P-HSA liposomes in BDL rats and tentatively characterised the receptors responsible for the in vivo uptake of these liposomes.
Materials and methods

Chemicals
Cholesterol (Chol), N-succinimidyl-S-acetylthioacetate (SATA) and polyinosinic acid (poly I) were from Sigma (St. Louis MO, USA). 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N- [4-(maleimidophenyl) 
Animals
Specified pathogen free (SPF) male Wistar or Wag/Rij rats (Harlan, Horst, The Netherlands) were housed under standard laboratory conditions with free access to food and water. The presented studies were approved by the local committee for care and use of laboratory animals.
Preparation of M6P-HSA
Human serum albumin N-substituted with mannose 6-phosphate (M6P) groups was prepared and characterised as described before [15] . The average number of M6P groups per albumin molecule was 29.
Preparation of liposomes
To prepare liposomes, appropriate volumes of POPC, CHOL and MPB-PE stock solutions in chloroform/methanol (9:1) were mixed to obtain a molar ratio 23:16:1. When indicated the non-degradable bilayer marker, 3 H-COE (0.25 μCi/μmol total lipid) was added. Liposomes were prepared as described before [21] . Briefly, organic solvent was evaporated under nitrogen, cyclohexan was added and the lipid solution was lyophilised overnight. The dried powdery lipids were hydrated in HN buffer (10 mM N-2-hydroxyethlpiperazine-N′-2-ethanesulfonic acid (HEPES), 135 mM NaCl) pH 6.7 for 1 h at room temperature. Liposomes were sized by extrusion through polycarbonate filters (Whaterman, Maidstone, Kent, UK) of 50 nm pore size using high-pressure extruder (Lipex, Vancouver, Canada). The phospholipid phosphorus content of each liposome preparation was assessed by a phosphate assay [22] . The total lipid concentration was calculated taking into account the amount of cholesterol in the liposomal preparation. Size and size distribution were determined by dynamic laser light scattering with a Nicomp submicron particle analyzer (NICOMP 380 ZLS, Santa Barbara, CA, USA). The mean diameter of the liposomes was obtained from the volume distribution curves produced by the particle analyzer. Zeta potential of the particles was measured in demineralised water (Nicomp 380). Liposomes without coupled protein were used in the experiments as control liposomes. M6P-HSA prepared as described above was coupled to MPB-PE liposomes by a sulfhydryl-maleimide coupling method using SATA as a heterobifunctional reagent, as reported before for aconitylated HSA [23] . Shortly, acetylthioacetate-M6P-HSA was separated from free SATA by gel chromatography and deacetylated by freshly prepared solution of 0.5 M hydroxylamine-HCl, 0.5 M HEPES and 25 mM EDTA, pH 7.0 added at the ratio of 10 μl per 100 μl of protein solution. Next, thioacetyl-M6P-HSA was incubated with MPB-PE containing liposomes for 4 h at room temperature at the ratio of 0.3 mg of protein per 1 μmol of total lipid. The coupling reaction was stopped by adding 8 mM N-ethylmaleimide (Sigma) solution in HN buffer pH 7.4. Liposomes were purified from uncoupled M6P-HSA by flotation on Opti-Prep™ (Axis-Shield PoCAS, Oslo, Norway) gradient. 2.5 ml of OptiPrep™ solution was mixed with 2 ml of incubation mixture containing liposomes and protein and overlaid with 0.6 ml of HN buffer pH 7.4. Liposomes were centrifuged (2 h at 40 000 rpm, 4°C) and collected between the buffer and the Opti-Prep™ layer after which the separation procedure was repeated. M6P-HSA coupled liposomes were extensively dialysed against HN buffer pH 7.4. Phospholipid phosphorus, protein content [24] , particle size and zeta-potential of M6P-HSA liposomes were analyzed again after protein coupling. Liposomes were stored under argon at 4°C and used within 2 weeks after preparation.
Given the average diameter of M6P-HSA liposomes (R) and the total amount of M6P-HSA coupled per μmol of total lipid (C MH ), it is of interest to determine the average number of M6P-HSA molecules coupled per liposome (ρ) as an indicator of the possible significance of the coupling. If one assumes the liposomes are approximately spherical with a diameter of R and the lipid is contained within a shell with a thickness of d bl at the boundary of the liposome, one can estimate this number by geometric arguments as
with V Ls the specific volume of a lipid molecule and M MH the molecular mass of M6P-HSA. [25] . When indicated, rats were used for in vivo experiments either 1 week (BDL-1) or 3 weeks (BDL-3) after bile duct ligation.
Blood disappearance and organ distribution
BDL-3 rats (250 g) were injected with 3 H-COE labelled liposomes at a dose of 1 μmol lipid per 100 g of body weight via the penile vein under O 2 /N 2 O/ Forene anaesthesia. When indicated, rats were injected with unlabelled M6P-HSA or HSA (13 mg/kg of body weight) or poly I (16 mg/kg of body weight), 5 min before injection of liposomes. Blood samples were taken 5, 10, 20, 30 min and 1 h after injection of liposomes. The total amount of radioactivity in the serum was calculated using the equation [26] :
The pharmacokinetic parameters were calculated from measured serum concentrations using the program Multifit [27] . The serum concentrations of uncoupled liposomes were fitted to a mono-exponential function and the appropriate pharmacokinetic parameters were derived. To calculate the pharmacokinetic parameters for serum elimination of targeted liposomes, we assumed that the preparation of the targeted liposomes contains small amounts of uncoupled liposomes, which, after rapid clearance of targeted liposomes from the blood, could be still detected in the serum samples for 1 h after injection. Therefore the serum concentrations of the targeted liposomes were fitted to a biexponential function and the pharmacokinetic parameters of the targeted liposomes were derived from the fastest exponential, assuming that the uncoupled liposomes were responsible for the slow second phase of the serum disappearance profile.
At the last time point, rats were sacrificed and liver, spleen, kidneys, lungs and heart were taken out for measurement of radioactivity as described before [23] .
HSC isolation
BDL-1 rats of 500 g were used to ensure harvesting of sufficient amounts of HSC from the livers. Rats were injected with 3 H-COE labelled liposomes at a dose of 2 μmol lipid per 100 g of body weight via the penile vein under O 2 /N 2 O/ Forene anaesthesia and after 1 h HSC were isolated as described before [28] . Radioactivity associated with the isolated cells was determined by liquid scintillation counting. The purity of the isolated HSC was assessed by immunohistochemical staining with antibodies directed against specific markers for HSC. Briefly, acetone/methanol (1:1) fixed cells were simultaneously incubated with mouse monoclonal antibodies directed against desmin and α-smooth muscle actin (both from Sigma). Endogenous peroxidase was inhibited with H 2 O 2 and cells were incubated, first with peroxidase conjugated rabbit-antimouse IgG (Dako Cytomation, Denmark), and then with peroxidase conjugated goat-anti-rabbit IgG (Dako). Antibody associated peroxidase was visualized with 3-amino-9-ethyl-carbazole (AEC). Cells were counterstained with Mayer's hematoxylin. Positively stained cells were counted in ten microscopic fields, magnification ×400 using Image J program (http://rsb.info.nih.gov/ij/).
Immunohistochemical analysis of liver sections
To identify the cells that bind M6P-HSA liposomes in fibrotic livers, M6P-HSA liposomes at a dose of 2 μmol lipid per 100 g of body weight were injected into BDL-3 rats (250 g) via the penile vein under O 2 /N 2 O/Forene anaesthesia. When indicated, rats were injected with poly I (16 mg/kg of body weight), 5 min prior to the administration of liposomes. Livers were harvested 20 min after injection of liposomes, snap frozen in isopentane and stored at − 80°C until further processing.
Cryostat sections of fibrotic livers (4 μm) were fixed in acetone. Immunohistochemical staining was performed as described earlier [15] . Briefly, M6P-HSA liposomes were stained with a rabbit polyclonal antibody directed against HSA (Cappel, Organon Teknika, Turnhout, Belgium). Endogenous peroxidase was inhibited with H 2 O 2 and sections were incubated, first with peroxidase conjugated goat-anti-rabbit IgG (Dako Cytomation, Denmark), and then with peroxidase conjugated rabbit-anti-goat IgG (Dako). Antibody associated peroxidase was visualized with AEC. Sections were counterstained with Mayer's hematoxylin.
When double immunostaining was performed, incubation of acetone fixed liver sections with antibody directed against HSA was followed by incubation with mouse monoclonal antibodies directed against cell proteins: desmin (Cappel), ED2 (Serotec Oxford, UK) and HIS 52 (a kind gift from Prof G. Molema UMCG, Groningen, The Netherlands) which are established markers for HSC, KC and LEC, respectively. After inhibition of endogenous peroxidase with H 2 O 2 and incubation with two secondary peroxidase conjugated antibodies for HSA detection as described above, liver sections were incubated with alkaline phosphatase conjugated rabbit-anti-mouse IgG (Dako). Antibodyassociated alkaline phosphatase was visualized with Naphtol AS-MX/Fast Blue (30 min at 37°C) and peroxidase activity with AEC (10 min at RT).
Detection of M6P/IGF II receptor in healthy and fibrotic livers 2.6.1. RNA isolation and RT-PCR
Total RNA from liver tissue of healthy and BDL-3 rats was isolated using RNeasy® Mini Kit (QIAGEN, Venlo, The Netherlands) according to the protocol of the manufacturer. RNA was measured by NanoDrop® ND-1000 Spectrophotometer (Wilmington, DE, USA) and analysed qualitatively by gel electrophoresis. Subsequently, synthesis of first strand cDNA from total RNA (10 μg) was performed with SuperScript™ III RNase H-Reverse Transcriptase (Invitrogen, Breda, The Netherlands) and 40 units RNaseOut inhibitor (Invitrogen) in a volume of 20 μl containing 250 ng random hexamers (Promega). The cDNA thus obtained was diluted with Millipore water to a concentration of 10 ng/μl. For the PCR reaction, 10 μl of liver-homogenate cDNA was applied in a total volume of 30 μl containing 2× ReddyMix™ PCR Master Mix (ABgene®, UK) and 10 μM primers. Primers for M6P/IGF II rat receptor were designed with the aid of Primer Designer from Scientific and Educational Software, based on the mRNA sequence for the rat insulin like growth factor II receptor (Accession number NM_012756). The sequence of M6P/IGF II receptor primers was as follows: forward 5′-GTGTCCTCTGGGTGTGGACT-3′, reverse 5′-CTCCTCCTTGCTGACCTTTG-3′ (Genosys, Haverhill, UK), giving a 241 bp product.
GAPDH (forward 5′-ACGGAAGGCCATGCCAGTGA-3′, reverse 5′-ACATGTTCCAGTATGACTCT-3′) (Biolegio BV, Nijmegen, The Netherlands) was used as house keeping gene (590 bp product). Thirty cycles of reaction at 95°C for 5 min, 95°C for 30 s, 58°C for 30 s, 72°C for 30 s and 72°C for 5 min were carried out using the GeneAmp® PCRSystem 9700 (Applied Biosystem). The polymerase chain reaction product was visualized on 1.5% agarose gel containing ethidium bromide.
Immunohistochemical analysis of liver sections
Cryostat sections (4 μm) of livers from healthy and 3 weeks BDL rats were fixed in acetone and incubated with a goat polyclonal antibody against M6P/IGF II receptor (Santa Cruz Biotechnology, Inc.). Subsequently, endogenous peroxidase was inhibited with H 2 O 2 , followed by incubation with peroxidase conjugated rabbit-anti-goat IgG (Dako) in the second step and with peroxidase conjugated goat-anti-rabbit IgG (Dako) in the third. Antibody associated peroxidase was visualised with AEC. Sections were counterstained with Mayer's hematoxylin.
Detection of SR-A expression by HSC
2.7.1. RNA isolation and RT-PCR HSC were isolated from livers of male Wistar rats (550-600 g) as described before [28] . Isolated HSC were cultured in DMEM containing 10% FCS, 100 U/ ml penicillin and 100 μg/ml streptomycin for 3 (quiescent phenotype) or 10 days (activated phenotype). LEC and KC were isolated from livers of male Wag/Rij rats (200-250 g) as described before [21] . LEC and KC were cultured in RPMI-1640 medium supplemented with 20% FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin and in case of LEC 10 ng/ml endothelial cell growth factor (Boehringer, Mannheim, Germany) for 2 days before being used in the experiments.
Total RNA from cultured HSC was isolated using Absolutely RNA Microprep kit (Stratagene, Amsterdam, The Netherlands) according to the protocol of the manufacturer. Synthesis of cDNA from total RNA (200 ng-10 μg) was performed as described above. cDNA was diluted to the concentration of 10 ng/ μl. For PCR reaction, 1 μl of primary-cell cDNA and 10 μl of liver-homogenate cDNA was applied in a total volume of 30 μl containing 2× ReddyMix™ PCR Master Mix (ABgene®). Primers for SR-A rat receptor were designed with the aid of Primer Designer from Scientific and Educational Software, based on the mRNA sequence for the rat scavenger receptor type A obtained from Genbank (Accession number XM_573919). The sequence of SR-A primers was as follows: forward 5′-ACTATAAATGGCTCCTCCGTTCA-3′, reverse 5′-AGA-CTCTGCAAGGACTTGGAAAT-3′ (Biolegio BV), giving a 440 bp product. GAPDH was used as house keeping gene. For isolated cells 26 cycles of reaction were carried out at 94°C for 5 min, 94°C for 30 s, 57°C for 45 s, 72°C for 45 s and 72°C for 7 min, and for liver homogenates 30 cycles were carried out using the GeneAmp® PCRSystem 9700 (Applied Biosystem). The polymerase chain reaction product was visualized on 1% agarose gel containing ethidium bromide.
Western blot
HSC and liver tissue from healthy and BDL-3 rats were homogenised in lysis buffer (0.02 M Tris-HCl, 5 mM EDTA, 2 mM EGTA, 0.1 M NaCl, 0.05% SDS, 0.5% NP-40, 10 μg/ml Protease Inhibitor Cocktail (Sigma)), separated by 10% polyacrylamide gel electrophoresis (30 μg protein of HSC per lane and 60 μg of liver homogenates per lane) and electroblotted onto nitrocellulose membrane (Bio-Rad). SR-A (Santa Cruz Biotechnology Inc.) primary antibody was used to detect scavenger receptor class A. Blots were developed using a chemiluminescence detection system (Lumi-LightPLUS Western Blotting substrate, Roche Diagnostic).
Statistical analysis
Statistical analysis of differences was performed by a two-tailed unpaired Student's t-test. Differences were considered significant when p b 0.05.
Results
Blood elimination and organ distribution
Blood disappearance of M6P-HSA liposomes in fibrotic rats 3 weeks after bile duct ligation (BDL-3) was compared to that of control liposomes of the same lipid composition but without surface grafted M6P-HSA. The average diameter of injected M6P-HSA liposomes was 102 ± 13 nm and 46 ± 15 μg (n = 9) of M6P-HSA was coupled per ìmol of total lipid. Combining Eq.
(1) with the literature values for the specific volume per lipid molecule V Ls (1.25 nm 3 ), the liposome bilayer thickness d bl (3.7 nm) [29] and the molecular weight M MH of M6P-HSA (about 69 kDa) [23] , we estimated an average of around 31 molecules of M6P-HSA coupled per liposome. Control liposomes had a diameter of 80 ± 2 nm (n = 5). The charge of the particles measured as zeta-potential was for M6P-HSA liposomes − 14.1 ± 3.3 mV and for control liposomes − 2.7 ± 2.2 mV. As early as 10 min after injection more than 90% of the injected dose of M6P-HSA liposomes had disappeared from the blood circulation, while of control liposomes only 45% had been cleared at that time point (Fig. 1) . One hour after injection, still 27% of all control liposomes were found in the blood while M6P-HSA liposomes had disappeared almost completely.
In order to study the specificity of the fast blood elimination of M6P-HSA liposomes in BDL rats, free M6P-HSA was injected into rats prior to administration of liposomes. Blood clearance of M6P-HSA liposomes was significantly attenuated by an excess of M6P-HSA (Fig. 1) . This resulted in an increase in the half life (t 1/2 ) of M6P-HSA liposomes in the circulation and in a decrease in the plasma clearance (CL) in M6P-HSA pre-treated rats (Table 1 ). An excess of M6P-HSA had no effect on the blood elimination of control liposomes. When BDL rats were injected with free HSA prior to the M6P-HSA liposome administration, the blood disappearance of these liposomes was not influenced (Fig. 1) , ( Table 1) .
The organ distribution of M6P-HSA liposomes in BDL rats was determined 1 h after injection of liposomes. At this time point 71.0 ± 3.5% of the injected dose of M6P-HSA liposomes had been taken up by the liver. The spleen accounted for 2.6 ± 0.2% of the injected dose of M6P-HSA liposomes, while the lungs contained 3.2 ± 0.6%. In other organs examined (heart and kidneys) uptake of M6P-HSA liposomes was less than 1%. 3 H-COE labelled liposomes were injected into BDL-3 rats at a dose of 1 μmol lipid per 100 g of body weight, at indicated time points blood samples were taken and the radioactivity was measured as described in Materials and methods. Data are presented as means ± SEM of 3 to 4 rats.
Control liposomes showed higher uptake in the spleen (8.5 ± 1.2% of the dose), but 50% less uptake was observed in the liver when compared to M6P-HSA liposomes (Fig. 2) .
In rats preinjected with free M6P-HSA, liver uptake of M6P-HSA liposomes was 15% lower than in untreated rats while increased accumulation of M6P-HSA liposomes was observed in lungs of M6P-HSA pre-injected rats (Fig. 2) .
Cellular localisation of M6P-HSA liposomes in fibrotic livers
Previously, we demonstrated in vitro that expression of the M6P/IGF II receptor in activated HSC increases compared to that in quiescent cells, both on the mRNA and the protein level [20] . In order to confirm these data, the in vivo expression of the M6P/IGF II receptor in the fibrotic liver was compared to that in the healthy organ (Fig. 3) . The PCR analysis showed that expression of the M6P/IGF II receptor in livers of BDL rats is high compared to expression in the livers of healthy rats. Immunohistochemical analysis of liver sections revealed that this receptor is predominantly expressed on hepatocytes in the control livers, whereas, in the livers of BDL-3 rats, positively stained cells with spindle-shape nuclei were observed in areas affected by disease. Together with our previous observations in vitro, these data demonstrate that HSC in the fibrotic liver express the M6P/IGF II receptor.
The localisation of M6P-HSA liposomes was determined in livers of BDL-3 rats using immunohistochemical methods. The morphological appearance of the immunostaining pattern observed following injection of M6P-HSA liposomes, with an antibody directed against HSA, indicated that these liposomes accumulate in non-parenchymal cells (Fig. 4A ) and were mainly distributed in the areas containing relatively low amounts of collagen (data not shown). By double-immunostainings we subsequently determined which of the non-parenchymal cell types contribute to the uptake of M6P-HSA liposomes. Liver sections were simultaneously stained for HSA and cell-specific markers for KC (ED 2), LEC (HIS 52) or HSC (desmin). Immunohistochemical analysis revealed that M6P-HSA liposomes co-localised with HSC (Fig. 4B), LEC (Fig. 4C ) as well as with KC (Fig. 4D) .
In addition, to quantify the uptake of M6P-HSA liposomes in HSC in fibrotic livers, these cells were isolated from BDL-1 rats injected with radioactively labelled liposomes. Uptake of M6P-HSA liposomes in HSC-enriched fractions was almost 7-fold that of control liposomes (Fig. 4E) . 70% of the cells in the HSCenriched cell fraction were HSC, while KC and LEC accounted for the remainder of the cells in this HSC fraction, as assessed by immunohistochemical staining against ED2 and HIS 52 (data not shown).
Effect of polyinosinic acid on blood elimination and intrahepatic distribution of M6P-HSA liposomes in BDL rats
The uptake of M6P-HSA liposomes by cultured HSC is mediated by M6P/IGF II receptors and most likely also by scavenger receptors (ScR) [20] . Firstly, the M6P/IGF II receptor can recognise the M6P moieties of the modified albumin. Secondly, the phosphate residues of the sugar group confer multiple negative charges to M6P-HSA while positive charges of albumin are cancelled out. The polyanionic character of the molecule may classify it as a ligand for ScR class A. We hypothesised that accumulation of M6P-HSA liposomes in LEC and KC may be mediated through ScR class A, since they do not express significant levels of M6P/IGF II receptor [18, 30] but are known to express different types of ScR, including ScR class A [31] . To examine this, 5 min prior to injection of M6P-HSA liposomes, poly I, which is a competitive inhibitor of ScR class A [32] was injected into BDL-3 rats. Blood elimination of liposomes was strongly inhibited in the poly I treated rats, compared to untreated animals (Fig. 5G) . As a result, t 1/2 of M6P-HSA liposomes was significantly increased and CL Table 1 Pharmacokinetic parameters of M6P-HSA liposomes and control liposomes in BDL-3 rats H-COE labelled liposomes were injected into BDL-3 rats at a dose of 1 μmol lipid per 100 g of body weight. One hour after injection of the liposomes the tissue distribution was determined as described in Materials and methods. Data are presented as means ± SEM of 3 rats, *p b 0.05; ***p b 0.001. decreased (Fig. 5G ) compared to M6P-HSA liposomes in rats that were not pre-injected with poly I (Table 1) . Immunohistochemical analysis of liver sections, 20 min after injection of M6P-HSA liposomes, revealed a distinct inhibition of the uptake of these liposomes by poly I in the liver that, however, did not lead to an increased uptake of liposomes elsewhere (data not shown). Further investigations into the cell types responsible for the uptake of M6P-HSA liposomes in poly I treated rats showed that accumulation of these liposomes in KC (Fig. 5A,  B) and LEC (Fig. 5C, D) is strongly inhibited by poly I. We did not observe a prominent difference in the uptake of M6P-HSA liposomes by HSC between poly I treated and untreated rats (Fig. 5E, F) .
The expression of ScR class A by quiescent HSC (qHSC) and activated HSC (aHSC) was checked at the mRNA and protein level. In qHSC and aHSC levels of ScR class A mRNA were comparable to that of KC and LEC (Fig. 6A) . However, Western blot analysis showed that qHSC abundantly express ScR class A while this protein was absent in aHSC (Fig. 6B) . ScR class A could also be detected in liver homogenates of healthy and fibrotic organs. The ratio of ScR class A to β-actin used as house keeping protein for qHSC was 0.72 while for aHSC 0.002.
Discussion
In the present study we characterised the targeting properties of M6P-HSA liposomes in a rat model of liver fibrosis induced by bile duct ligation. We showed that M6P-HSA liposomes are rapidly cleared from the blood circulation in diseased rats and mainly accumulate in the liver. This fast elimination of M6P-HSA liposomes from the blood by the target organ and the limited accumulation in other organs demonstrate that the organ distribution profile of M6P-HSA liposomes is highly suitable to deliver drugs to a diseased liver. The prolonged blood circulation time of M6P-HSA liposomes in animals treated with M6P-HSA in combination with lung injury that has been reported in BDL rats may have caused increased lung uptake in these rats [33] . Particularly, the development of pulmonary intravascular macrophages (PIM) in the lungs of BDL rats may play a role in this elevated accumulation. Similarly, a shift in uptake from the liver to the lungs caused by PIM was observed in BDL rats injected with adenoviral particles [34, 35] . The rapid blood clearance of M6P-HSA liposomes was blocked by pre-injection of M6P-HSA, but not by HSA, indicating a specific recognition of mannose 6-phosphate groups by cells within the liver.
In the livers of BDL rats (biliary fibrosis), collagen deposition predominately surrounds the proliferating bile ducts and to a lesser extent is localized in zones 1 and 2 (central vein and periportal area) of the liver [12] . M6P-HSA liposomes mainly distribute to zones 1 and 2 i.e. the areas containing relatively low amounts of collagen. The regions of the liver characterized by massive deposition of extracellular matrix proteins were clearly less accessible to liposomes. Changes in the hepatic architecture associated with fibrosis most likely interfere with the distribution of M6P-HSA liposomes within the liver. In the healthy liver, endothelial cells are fenestrated with pores of 150 to 175 nm in diameter [36] , that enable a close contact between blood and the space of Disse where HSC are situated. In the fibrotic liver, endothelial cells at least partly lose their fenestrations [37] and, in addition, the contraction of HSC causes an increased vascular resistance in the sinusoids [11] . As a result, the highly fibrotic areas of the liver may not be readily accessible to macromolecules. The size of M6P-HSA liposomes (approximately 100 nm) allows them to pass fenestrations in endothelial cells in those parts of the fibrotic livers where they are still present and functional.
The high accumulation of M6P-HSA liposomes compared to control liposomes in HSC-enriched fractions isolated from BDL rat livers demonstrates that M6P-HSA liposomes are taken up by HSC in fibrotic livers. These data are in agreement to our previous study in which we demonstrated a 3,5-fold higher uptake of M6P-HSA liposomes as compared to control liposomes in cultured activated HSC [20] .
Immunohistochemical examination revealed that M6P-HSA liposomes also accumulate in two other major non-parenchymal cells populations: liver endothelial cells (LEC) and Kupffer cells (KC). It is known that activated HSC express an increased number of M6P/IGF II receptors [17, 18] . In contrast, no significant levels of M6P/IGF II receptor expression were observed on LEC [18] and KC [30] . Therefore, in the recognition of M6P-HSA liposomes by KC and LEC scavenger receptors (ScR) might be involved. ScR are known to bind anionic (macro) molecules and are abundantly expressed by KC and LEC. The current study showed that polyinosinic acid (poly I), an established competitive inhibitor of ScR class A, strongly prevented the rapid blood clearance of M6P-HSA liposomes and exerted an inhibitory effect on the association of these liposomes with KC and LEC in fibrotic livers. Uptake of M6P-HSA liposomes by HSC was still observed in poly I treated rats (Fig. 5F ), which indicates that liposomes are recognised by other types of receptors on these cells, in particular M6P/IGF II receptors.
However, we cannot exclude the presence of scavenger receptor class A on HSC. We reported before, that cultured HSC take up liposomes modified with polyanionic albumin, aconitylated HSA and that this process can be inhibited by poly I [20] . In the present study, we demonstrated that at the mRNA level ScR class A was present in both quiescent and activated HSC while at the protein level the expression of ScR class A decreased in the activated cells. The molecular weight of ScR class A found in the Western blot analysis was slightly lower (64 kDa) than indicated by manufacturer of the antibody (75 kDa). However, different molecular masses (72 and 65 kDa) of mature bovine ScR class A type II receptor have been reported [38] . Although M6P/IGF II receptors and scavenger receptors considerably contribute to the uptake of M6P-HSA liposomes, involvement of other receptors cannot be ruled out.
The development of liver fibrosis is a complex process, in which different types of cells are involved. The initial step, the impairment of hepatocytes, results in the release of reactive oxygen species and fibrotic and inflammatory cytokines stimulating in turn KC, LEC and HSC, as well as in recruitment of cells of the immune system. KC, LEC and inflammatory cells further promote activation of HSC, leading to transformation of these cells into an activated phenotype characterised by a high proliferation rate, production of collagen and mediators of fibrosis, which in an autocrine manner maintain the activated status of stellate cells [10] . The uptake of M6P-HSA liposomes by KC and LEC, next to the uptake in HSC has to be taken into account when an antifibrotic drug is chosen for encapsulation H-COE labelled M6P-HSA liposomes were administered at a dose of 10 μmol/kg body weight into anaesthetized BDL-3 rats. Poly I (16 mg/kg of body weight) was injected 5 min before M6P-HSA liposomes. Blood samples were taken at indicated time points and analyzed as described in Materials and methods. Data of blood elimination of M6P-HSA liposomes in poly I treated rats are presented as means ± SEM of 3 rats. Pharmacokinetic parameters of M6P-HSA liposomes in poly I treated rats were inferred from fits over the mean of 3 rats and given as ± SE. t 1/2 , half life; CL, plasma clearance; V, volume of distribution; AUC, area under the fitted concentration-time curve. into M6P-HSA liposomes. Since HSC are the major producers of collagen in the fibrotic liver, specific inhibitors of its production which are not harmful for KC and LEC would seem to be suitable candidates for incorporation into M6P-HSA liposomes. However, the multiple targeting properties of M6P-HSA liposomes to all relevant regulatory cells of the fibrotic process offer the possibility to deliver simultaneously anti-inflammatory drugs to KC and LEC and antifibrotic compounds to HSC in the diseased liver. Currently, there are several known compounds which could be possibly used in this approach. Antioxidants such as quercetin and resveratrol inhibit proliferation and activation of HSC, and in addition decrease the production of nitric oxide (NO) and tumor necrosis factor α (TNF-α) by KC [39] . Alternatively, thiazolidinediones, which are peroxisome proliferator-activated receptor-γ agonists, inhibit HSC collagen production [40] as well as proliferation and chemotaxis of these cells [41] . In KC, these compounds reduce TNF-α and NO production [42] . This strategy for attenuation of liver fibrosis may be efficient, since the complexity of the disease suggests that a simultaneous interference with multiple pathways of the fibrotic process in different cell types may be the most successful antifibrotic approach.
In conclusion, we have shown that liposomes coupled with M6P-HSA are potentially effective drug carriers, targeted to the non-parenchymal cells, including HSC, which play a crucial role in the development of liver fibrosis. The recognition of M6P-HSA liposomes by HSC, LEC and KC in the fibrotic liver is M6P-HSA specific, involving both M6P/IGF II and scavenger receptors. The multiple targeting properties of M6P-HSA liposomes open up new possibilities for pharmacological interference with a disease as complex as liver fibrosis.
